Diabetic retinopathy represents a major public health challenge, says Ioanna Anastasiou, of the National and Kapodistrian University of Athens, Athens, Greece, who led the research
However, for people struggling with obesity, insulin resistance, or type 2 diabetes, the natural GLP-1 response can be insufficient
Novo Nordisk Settles Ozempic Patent Case The Danish company Novo Nordisk and Viatris' Mylan Pharmaceuticals have settled their patent dispute before the Patent Trial and Appeal Board (PTAB or the Board) involving the weight-loss drugs Ozempic and Wegovy
Tell your doctor immediately if you experience chest pain, increased pulse rate, rapid, strong, irregular heartbeat, excessive sweating, or any other unusual event
Consider scheduling an appointment with your healthcare provider if you experience weight regain of approximately 3-5% of your body weight within a few weeks of stopping the medication, though specific thresholds should be individualized